Researchers study under-recognised and under-treated prothrombotic condition: High platelet reactivity despite treatment

May 6, 2013

Within the past decade, the variability in pharmacodynamic response and moderate antiplatelet efficacy of clopidogrel has raised major concerns, in particular because it is associated with an increased risk for ischemic events in PCI patients. Certainly, the public should have detailed knowledge about the incidence of high on-treatment platelet reactivity (HTPR) and its impact on clinical outcomes.

For this reason and to demonstrate how to diagnose and treat this pro-thrombotic condition, Prof. Dr. Kurt Huber, Director, 3rd Dept. Med., Cardiology and Emergency Medicine, Wilhelminen Hospital, Vienna, Austria, and Prof. Dr. Karsten Schör, Director em. Institute of Pharmacology and , Heinrich-Heine University Düsseldorf, Germany, and their co-authors have written a Theme Issue in the journal Thrombosis and Haemostasis, addressing various facets of HTPR.

HTPR - affecting non- or low-responders to treatment with P2Y12-receptor inhibitors (such as ) - is known to trigger stent-thrombosis, , and . The variability in response could be linked to impacting the activity of the cytochrome P450 enzyme in the liver. Underlying mechanisms seem to include and drug interactions (omeprazole and esomeprazole). Yet other agents lead to a lower rate of HTPR than clopidogrel. Therefore, regulatory agencies and cardiac societies suggest the use of other anti-platelet medications or alternative dosing strategies for clopidogrel in patients with reduced effectiveness to this P2Y12-receptor inhibitor.

The authors of the Theme Issue discuss the clinical value of new P2Y12-receptor inhibitors and also try to identify potential candidates who are most likely to benefit from the new agents.

In this Theme Issue which is part of the May issue of Thrombosis and Haemostasis, several reasons for "high on-treatment platelet reactivity" are reviewed. According to the Guest Editors Huber and Schör, researchers might benefit from the very latest 'state of the art' level of knowledge of pathophysiological pathways and detailed information about the pharmacodynamic and pharmacokinetic mechanisms of old and new P2Y12-receptor antagonists provided by this theme issue. Moreover, the novel diagnostic tests and therapeutic strategies discussed herein might also be interesting to health care providers as they would know which are the best tests to apply, how to direct a more critical use of available platelet function tests to detect HTPR; and to get to know which combination strategies are to be favored at present.

Explore further: Results of the TRIGGER-PCI trial reported at TCT 2011

More information: Huber K, Schör K: Theme Issue: High on-treatment platelet reactivity. Thromb Haemost 2013; 109: 789-853. …

Related Stories

Results of the TRIGGER-PCI trial reported at TCT 2011

November 9, 2011
A clinical trial comparing prasugrel to clopidogrel for patients with high on-clopidogrel platelet reactivity (HCPR) following percutaneous coronary intervention (PCI) was ended early due to relatively few occurrences of ...

Lower achieved platelet reactivity associated with better cardiovascular

August 30, 2011
Compared to patients who had persistently high platelet reactivity, those who achieved low platelet reactivity, according to the VerifyNow P2Y12 Test, had a reduced incidence of cardiovascular death, heart attack and stent ...

Global platelet reactivity and high risk ACS patients

August 28, 2012
Global platelet reactivity is more effective than responsiveness to clopidogrel in identifying acute coronary syndrome (ACS) patients at high risk of ischemic events, according to research presented at ESC Congress 2012.

Antiplatelets: 1 person, 1 dose?

April 14, 2011
An international consortium of scientists, including major contributions from the Montreal Heart Institute, demonstrates that the "one-size fits all" strategy of uniformly doubling the dose of an antiplatelet drug, clopidogrel, ...

Low responsiveness to clopidogrel predicts stent thrombosis, heart attack: But is not directly linked to death

October 25, 2012
Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are more likely to have blood clots form on the stent and suffer a possible heart attack; conversely, patients with higher ...

30-day results of ADAPT-DES registry reported at TCT 2011

November 9, 2011
The relationship of platelet responsiveness to antiplatelet medications; and, the correlation of poor response, and overall platelet aggregation while on dual antiplatelet therapy to the risk of drug-eluting stent thrombosis ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.